FACULTY BIOGRAPHIES
Dr. Fares Al-Ejeh (PhD)
- Emailfalejeh@hbku.edu.qa
- Phone+974 31187870
Biography
Associate Professor Fares Al-Ejeh was awarded his Bachelor of Biotechnology degree, and his PhD from the University of Wollongong (NSW, Australia). His first post-doctoral position was industry-funded by Oncaidia Ltd at the Royal Adelaide Hospital/Hanson Institute. .
After five years in industry-oriented research, Dr. Al-Ejeh started his academic career at one of Australia's largest research institutes, the QIMR Berghofer Medical Research Institute. At QIMR, he established his own group, Personalised Medicine, in 2015. His track record includes two granted patents on Apomab and five submitted patent applications undergoing evaluation. He has more than 50 peer-reviewed publications focusing on cancer diagnostics and therapeutics with focus on translational medical research.
Dr. Al-Ejeh has contributed as a keynote speaker at several conferences and as a member of several panels for grant reviews in Australia and internationally. He is an Associate Member of the Australian Academy of Health and Medical Sciences (AAHMS) and an adjunct Associate Professor at the Faculty of Medicine, University of Queensland, Australia in recognition of his teaching and supervision of postgraduate students.
Research Interests
-
Personalized/Precision Oncology
-
Multi-omics
-
Novel Biomarkers and Drug Targets
-
Breast Cancer
Experience
Senior Scientist
Qatar Biomedical Research Institute/HBKU, Translational Oncology Research Center. Doha, Qatar.
2020 - presentTeam Head (Faculty) and Senior Research Fellow
QIMR Berghhofer Medical Research Institute. Brisbane, Australia
2010 - 2019
Senior Researcher and Chief Scientific Officer
Oncaidia Ltd. and the Royal Adelaide Hospital, Hanson Institute. Adelaide, Australia
2005 - 2009
Education
Bachelor of Biotech (Honours)
University of Wollongong (NSW/Australia)
2001Ph.D. (Cancer Biology)
University of Wollongong (NSW/Australia)
2005
Selected Publications
-
Al-Nesf, M.A.Y., Abdesselem, H.B., Bensmail, I. et al. Al-Ejeh, F.
Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications. Nature Communications. 2022; 13, 946. https://doi.org/10.1038/s41467-022-28639-4 https://www.nature.com/articles/s41467-022-28639-4
2022 -
Saunus JM, De Luca XM, Northwood K, et al.
Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer. NPJ Breast Cancer. 2022;8(1):57. https://doi.org/10.1038/s41523-022-00425-x https://pubmed.ncbi.nlm.nih.gov/35501337/
2022 -
Kelly GM, Al-Ejeh F, McCuaig R, et al.
G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma. Clin Cancer Res. 2021;27(9):2624-2635. https://doi.org/10.1158/1078-0432.CCR-20-3463https://pubmed.ncbi.nlm.nih...
2021 -
Miranda M. et al., Al-Ejeh F.
A short ERK5 isoform modulates nucleocytoplasmic shuttling of active ERK5 and associates with poor survival in breast cancer. bioRxiv 2021.03.23.436061; https://doi.org/10.1101/2021.03.23.436061 https://www.biorxiv.org/content/10.1101/2021.03.23.436061v1.abstract
2021 -
Casciello F, Al-Ejeh F, Miranda M, et al.
G9a-mediated repression of CDH10 in hypoxia enhances breast tumour cell motility and associates with poor survival outcome. Theranostics. 2020;10(10):4515-4529. Published 2020 Mar 15. https://doi.org/10.7150/thno.41453 https://pubmed.ncbi.nlm.nih.gov/32292512/
2020 -
Saleh R, Sasidharan Nair V, Toor SM, et al. Al-Ejeh F. and Elkord E.
Differential gene expression of tumor-infiltrating CD8+ T cells in advanced versus early-stage colorectal cancer and identification of a gene signature of poor prognosis. J Immunother Cancer. 2020;8(2):e001294. https://doi.org/10.1136/jitc-2020-001294 https://pubmed.ncbi.nlm.nih.gov/32948653/
2020 -
Sasidharan Nair V, Saleh R, Taha RZ, et al. Al-Ejeh F. and Elkord E.
Differential gene expression of tumor-infiltrating CD4+ T cells in advanced versus early stage colorectal cancer and identification of a gene signature of poor prognosis. Oncoimmunology. 2020;9(1):1825178. Published 2020 Sep 30. https://doi.org/10.1080/2162402X.2020.1825178 https://pubmed.ncbi.nlm.nih.gov/33101776/
2020 -
Kalita-de Croft P, Lim M, Chittoory H, et al.
Clinicopathologic significance of nuclear HER4 and phospho-YAP(S127) in human breast cancers and matching brain metastases. Ther Adv Med Oncol. 2020;12:1758835920946259. https://doi.org/10.1177/1758835920946259 https://pubmed.ncbi.nlm.nih.gov/33014146/
2020 -
Ferreira MA, Gamazon ER, Al-Ejeh F, et al.
Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019;10(1):1741. https://www.ncbi.nlm.nih.gov/pubmed/30988301
2019 -
Wiegmans AP, ... Al-Ejeh F, Möller A.
Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer. JCI Insight, 2019;5. pii: 124092. https://www.ncbi.nlm.nih.gov/pubmed/30830863
2019 -
Offenhäuser C (co-first), Al-Ejeh F (co-first), et al.
EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma. Cancers (Basel), 2018 ;10(12). pii: E519. https://www.ncbi.nlm.nih.gov/pubmed/30562956
2018 -
Wu L, Shi W, Long J, Guo X, Michailidou K, Beesley J, Bolla MK, Shu XO, Lu Y, Cai Q, Al-Ejeh F, et al.
A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018; 50(7):968-978. https://www.ncbi.nlm.nih.gov/pubmed/29915430
2018 -
Johnson J, ..., Al-Ejeh F.
Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient. Breast Cancer Res Treat, 2018;170(1):179-188. https://www.ncbi.nlm.nih.gov/pubmed/29468485
2018 -
Saunus JM, ..., Al-Ejeh F (co-last), Lakhani SR (co-last).
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research. Breast Cancer Res Treat, 2018;167(1):289-301. https://www.ncbi.nlm.nih.gov/pubmed/28889351
2018 -
Betts JA (co-first), Moradi Marjaneh M (co-first), Al-Ejeh F (co-first), et al.
Long Noncoding RNAs CUPID1 and CUPID2 Mediate Breast Cancer Risk at 11q13 by Modulating the Response to DNA Damage. American Journal of Human Genetics, 2017;101(2):255-266. https://www.ncbi.nlm.nih.gov/pubmed/28777932
2017 -
Wiegmans AP, Miranda M, Wen SW, Al-Ejeh F (co-last), Möller A. (co-last).
RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy. Oncotarget, 2016, 13;7(37):60087-60100. https://www.ncbi.nlm.nih.gov/pubmed/27507046
2016 -
Al-Ejeh F, et al.
Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. Oncogenesis, 2014;3:e100. https://www.ncbi.nlm.nih.gov/pubmed/24752235
2014 -
Al-Ejeh F, et al.
Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. Clinical Cancer Research, 2014;20(12):3187-97. https://www.ncbi.nlm.nih.gov/pubmed/24838526
2014 -
Al-Ejeh F, et al.
Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer. Oncotarget, 2014;5(10):3145-58. https://www.ncbi.nlm.nih.gov/pubmed/24762669
2014 -
Al-Ejeh F, et al.
Postchemotherapy and tumor-selective targeting with the La-specific DAB4 monoclonal antibody relates to apoptotic cell clearance. Journal of Nuclear Medicine, 2014;55(5):772-9. https://www.ncbi.nlm.nih.gov/pubmed/24676755
2014 -
Al-Ejeh F, et al.
Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. Journal of Nuclear Medicine, 2013;54(6):913-21. https://www.ncbi.nlm.nih.gov/pubmed/23564760
2013 -
All publications at https://www.ncbi.nlm.nih.gov/pubmed/?term=al-ejeh
MYHBKU LOGIN